血清CA125、CEA联合检测在卵巢肿瘤中的诊断价值

目的　探讨血清CA1 2 5和CEA联合检测在卵巢肿瘤诊断中的价值。方法　采用酶联免疫分析法(ELISA)对卵巢恶性肿瘤、良性肿瘤及子宫内膜异位症患者血清CA1 2 5和CEA含量进行检测。结果　卵巢恶性肿瘤CA1 2 5含量明显高于对照组、卵巢良性肿瘤、交界性瘤及子宫内膜异位症 (P <0 0 1 ) ;子宫内膜异位症及盆腔炎CA1 2 5含量高于对照组及卵巢良性肿瘤 (P <0 0 5 )。结论　单项检测CA1 2 5对卵巢上皮性癌诊断性能最佳 ,对子宫内膜异位症也有较理想的诊断价值。CA1 2 5、CEA联合检测对卵巢恶性肿瘤的诊断无明显价值。

Diagnosis Value of Determination of Serum CA125 and CEA in Patients with Ovarian Tumors

Objective To study the diagnosis value of combined measurement of the cancer antigen 125 (CA125) and CEA in patients with ovarian tumors.Methods ELISA was used to measure the levels of serum CA125 and CEA in patients with benign ovarian tumor, malignant ovarian tumor and endometriosis. ResultsSerum CA125 level was significantly higher in patients with malignant ovarian tumor than that in those with benign or borderline ovarian tumor or endometriosis and in control group(P<0.01). Serum CA125 level was higher in patients with endometriosis and pelvic infection than that in those with benign ovarian tumor and in control group(P<0.05). Conclusion The single detection of CA125 may be the best method of diagnosing ovarian epithelioma, and has greater value in diagnosing endometriosis. The combind detection of CA125 and CEA doesn't have significant value in diagnosing malignant ovarian tumor.